Gotham Asset Management LLC Raises Stake in Charles River Laboratories International, Inc. $CRL

Gotham Asset Management LLC increased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 17.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 315,755 shares of the medical research company’s stock after buying an additional 46,594 shares during the quarter. Gotham Asset Management LLC’s holdings in Charles River Laboratories International were worth $49,403,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Principal Financial Group Inc. raised its holdings in shares of Charles River Laboratories International by 84.5% during the third quarter. Principal Financial Group Inc. now owns 104,719 shares of the medical research company’s stock worth $16,384,000 after purchasing an additional 47,954 shares during the last quarter. Penserra Capital Management LLC purchased a new stake in Charles River Laboratories International in the third quarter valued at $533,000. Madison Asset Management LLC acquired a new stake in Charles River Laboratories International during the 3rd quarter worth about $1,935,000. Cooke & Bieler LP grew its position in Charles River Laboratories International by 0.9% during the 3rd quarter. Cooke & Bieler LP now owns 603,877 shares of the medical research company’s stock worth $94,483,000 after purchasing an additional 5,100 shares during the period. Finally, Invesco Ltd. raised its stake in shares of Charles River Laboratories International by 11.6% during the 2nd quarter. Invesco Ltd. now owns 1,237,143 shares of the medical research company’s stock valued at $187,712,000 after buying an additional 128,785 shares during the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

CRL has been the subject of several analyst reports. Barclays decreased their price objective on Charles River Laboratories International from $215.00 to $200.00 and set an “overweight” rating for the company in a report on Thursday, February 19th. UBS Group lifted their price target on Charles River Laboratories International from $170.00 to $175.00 and gave the company a “neutral” rating in a research report on Wednesday, February 25th. Mizuho decreased their price target on Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating for the company in a report on Friday, February 20th. Evercore upped their price objective on Charles River Laboratories International from $250.00 to $260.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Charles River Laboratories International in a research note on Wednesday, January 21st. Ten investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Charles River Laboratories International presently has an average rating of “Moderate Buy” and an average price target of $203.57.

Charles River Laboratories International Price Performance

NYSE:CRL opened at $155.61 on Monday. The company has a quick ratio of 1.02, a current ratio of 1.29 and a debt-to-equity ratio of 0.67. Charles River Laboratories International, Inc. has a 52 week low of $91.86 and a 52 week high of $228.88. The stock’s 50-day moving average price is $191.59 and its 200-day moving average price is $181.13. The stock has a market capitalization of $7.66 billion, a PE ratio of -52.57, a price-to-earnings-growth ratio of 2.66 and a beta of 1.64.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, February 18th. The medical research company reported $2.39 earnings per share for the quarter, topping analysts’ consensus estimates of $2.33 by $0.06. The company had revenue of $994.23 million during the quarter, compared to analysts’ expectations of $986.98 million. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.Charles River Laboratories International’s quarterly revenue was down .8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.66 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. As a group, equities analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Key Headlines Impacting Charles River Laboratories International

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Zacks raised its FY2027 EPS view to $11.62 (from $11.30), signaling stronger full‑year outlook and supporting a higher valuation multiple. Zacks FY2027 boost
• Positive Sentiment: Zacks lifted FY2026 EPS to $10.78 (from $10.68), implying near‑term margin or revenue improvement versus prior assumptions. Zacks FY2026 boost
• Positive Sentiment: Zacks published FY2028 EPS of $12.12, reflecting continued expected earnings growth beyond FY2027. Long‑term upgrades can lift investor sentiment. Zacks FY2028 outlook
• Positive Sentiment: Multiple quarterly raises: Q3 2026 to $2.86, Q3 2027 to $3.02, Q4 2026 to $3.02, and Q4 2027 to $3.32 — these sequential upgrades point to improving quarterly momentum. Zacks quarterly upgrades
• Positive Sentiment: Zacks raised mid‑2026 quarterly views (Q2 2026 to $2.85 and Q2/Q3 2026 lifts), indicating expectations for recovery or stronger demand in the upcoming fiscal periods. Zacks mid‑2026 raises
• Neutral Sentiment: Zacks’ estimates differ from the consensus full‑year figure repeatedly cited ($9.36), meaning analyst views remain divergent; the Zacks upgrades imply upside versus consensus but do not change consensus itself. Consensus vs Zacks
• Negative Sentiment: Zacks lowered Q1 2026 EPS from $2.39 to $2.05, a material near‑term cut that could pressure the next quarter’s reported results and short‑term sentiment. Zacks Q1 2026 cut
• Negative Sentiment: Zacks slightly trimmed Q2 2027 to $2.65 (from $2.67), a minor downgrade but another signal of some variability in near‑term cadence. Zacks Q2 2027 trim

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.